HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Emphysema due to alpha-antitrypsin deficiency: familial study of the YBARCELONA variant.

Abstract
A 39-year-old female patient, an ex-smoker with an 8-pack-year smoking history and severe pulmonary emphysema of early onset, received a diagnosis of alpha(1)-antitrypsin (AAT) deficiency and proved to be a carrier of a new deficient variant, YBARCELONA, derived from the normal M1 variant with two substitutions: one in exon III and the other in exon V. AAT genotype of eight members of the same family and study of lung function of the index case and family members at baseline and after 6 years of follow-up were performed. Five subjects were PiYM, with intermediate serum AAT concentrations and normal pulmonary function. No changes were observed over 6 years in pulmonary function of the PiYM patients who were nonsmokers; however, the PiYY index case presented worsening of pulmonary function with FEV(1) of 33%. The heterozygotes PiYM have AAT concentrations similar to the PiMZ and, at 6 years, the nonsmokers presented no worsening in pulmonary function. The risk associated with this variant in its heterozygous form may be similar to that described for PiMZ.
AuthorsMarc Miravitlles, Sara Vilà, Rosendo Jardí, Cristian de la Roza, Francisco Rodríguez-Frías, Rafael Vidal
JournalChest (Chest) Vol. 124 Issue 1 Pg. 404-6 (Jul 2003) ISSN: 0012-3692 [Print] United States
PMID12853554 (Publication Type: Case Reports, Journal Article)
Topics
  • Adult
  • Female
  • Follow-Up Studies
  • Genetic Variation
  • Heterozygote
  • Humans
  • Male
  • Pulmonary Emphysema (diagnosis, genetics)
  • Respiratory Function Tests
  • Smoking (adverse effects)
  • Time Factors
  • alpha 1-Antitrypsin Deficiency (complications, diagnosis, genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: